Philadelphia Inquirer: Opioid Approvals Should Protect Public Health


Published on March 9, 2018

Gail Groves Scott MPH'16, manager of the Substance Use Disorders Institute at USciences, and Daniel Ventricelli PharmD, MPH, co-authored a commentary for the Philadelphia Inquirer about the FDA's regulations of abuse deterrent formulations of opioids.

From the commentary:
As health-care educators and professionals with experience in the industry, we support the FDA’s action, and the new direction it signals: that drug approval decisions should give greater consideration to population health.

The FDA should use this approach to re-evaluate drugs already on the market, plus new ones on the horizon. Policymakers need to rethink financial and legal advantages afforded to pharmaceutical manufacturers for new formulations of old drugs. ADFs are just as addictive as previous formulations of opioid medications and unfortunately have been associated with unintended harms and consequences.

Read the full commentary on Philly.com.

Categories:  Substance Use Disorders InstituteFacultySUDI